There are dangers in excluding the unvaccinated from jury service in US patent cases
Courts striking-out those who have not had covid-19 jabs may unintentionally be eliminating people from diverse demographics holding multiple world views
Courts striking-out those who have not had covid-19 jabs may unintentionally be eliminating people from diverse demographics holding multiple world views
German mRNA innovators poised for fight over vaccine revenues in the Dusseldorf Regional Court
The pandemic has brought the difficulties of bypassing life sciences IP into plain view
Enanta Pharmaceuticals is seeking a share of blockbuster antiviral revenues
24 June 2022
Data on law firms ranked by 2021 grants shows a slide that may link to filing strategies changing because of pandemic-induced budget cuts
17 June 2022
The agreed IP waiver is less far-reaching than the original proposal, but underscores how the pandemic has impacted IP politics.
17 June 2022
Despite the close attentions of a tornado and the deadening heatwave that preceded and followed it, delegates and speakers in Chicago were in good form for the final day of this year's event
15 June 2022
BoA President Carl Josefsson also tells IAM that backlog reduction efforts are on track and the organisation is turning its attention toward timeliness of proceedings
27 May 2022
The company claims any infringing uses of its vaccine are insulated from liability under compulsory licensing law
17 May 2022
If compulsory licensing is used in Turkey, it is imperative that the individual requirements of each case are considered. This is especially important when it comes to facilitating access to medical treatments for covid-19.
30 March 2022
Several new legal actions have been launched by lipid nanoparticle technology owners
28 March 2022
There are reports of a compromise deal agreeed by the US, EU, India and South Africa, but no official confirmation
16 March 2022
Petro Terblanche speaks to IAM about the mRNA innovator’s expanded IP commitment
14 March 2022
Get unlimited access to all IAM content